Last checked at 15 Dec 2023 17:14
London stocks log weekly gains as cenbank fest ends
FTSE 100 down 1.0%, FTSE 250 off -0.3%
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat4
AZN Share
Trades9,065
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,332.00
Bid:
12,344.00
Ask:
12,346.00
Change:
68.00 (0.55%)
Spread:
2.00 (0.016%)
Open:
12,268.00
High:
12,388.00
Low:
12,256.00
Prev. Close:
12,264.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca to raise ?2.7bn for cancer collab, bond repayment
Fri, 29th Mar 2019 08:03
(Sharecast News) - AstraZeneca plans to raise $3.5bn (£2.7bn) in a share placing to fund a new cancer drug collaboration with Japan's Daiichi Sankyo and repay some of its bonds.The collaboration is to accelerate the development of the Japanese company's novel HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan, expanding the treatment across breast and other cancers.Astra will pay $1.35bn of the net placing cash to Daiichi Sankyo, of which half will be paid up-front and the rest in 12 months' time. There are also expected to be roughly $1bn of approval and sales-related contingent milestone payments starting from next year until 2022.Trastuzumab deruxtecan is currently in development for the treatment of multiple HER2-expressing cancers, including breast and gastric cancer, and in patients with HER2-low expression.In 2017, the US regulator awarded the conjugate was breakthrough therapy designation for the treatment of patients with HER2-positive, locally-advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after trastuzumab emtansine.Astra chief executive Pascal Soriot said: "We believe that trastuzumab deruxtecan could become a transformative new medicine for the treatment of HER2-positive breast and gastric cancers."In addition, it has the potential to redefine breast cancer treatment as the first therapy for HER2-low expressing tumours. It also has the potential to treat other HER2-mutated orHER2-overexpressing cancers, including lung and colorectal cancers. We are proud to be working with Daiichi Sankyo, a long-term collaborator of AstraZeneca in other disease areas."Another $1bn of the placing funds will be used to pay off its 1.95% bonds due on 18 September 2019, with the remainder of the placing proceeds held as cash to help strengthen the balance sheet.
More News
15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more13 Dec 2023 17:07
UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision
UK economy shrinks by 0.3% in October
*Read more12 Dec 2023 16:00
London close: Stocks slip as investors digest US inflation
(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.
Read more12 Dec 2023 12:07
London midday: FTSE still firmer ahead of US inflation print
(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:53
LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI
(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.
Read more12 Dec 2023 08:37
AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion
(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:16
AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn
(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.
Read more12 Dec 2023 02:00
UK companies pause China investment decisions as economy slows, survey shows
BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.
Read more11 Dec 2023 08:15
AstraZeneca says danicopan tests well as blood disorder treatment
(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more1 Dec 2023 08:52
LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI
(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.
Read more